|
Achieved 79.7 Billion KRW in Q3 Sales, Marking 17 Consecutive Quarters of Double-Digit Growth
2016.11.15
|
|---|
|
- Achieved cumulative Q3 sales of 79.7 billion KRW and operating profit of 8.6 billion KRW, representing over 20% year-on-year growth - Sustained strong performance across all major business sectors, including pharmaceuticals, wellness, and veterinary medicine - “We expect to maintain this growth momentum into Q4, targeting annual sales of 110 billion KRW and operating profit of 12 billion KRW”
Daehan New Pharm continued its double-digit growth for the 17th consecutive quarter, maintaining an average sales increase of around 20%.
According to consolidated results for the third quarter, the company reported cumulative sales of 79.7 billion KRW and operating profit of 8.6 billion KRW. Compared to the same period last year, sales rose by 19.1% and operating profit by 17.4%, marking the 17th consecutive quarter of double-digit growth since Q3 2012—a record of consistent performance that holds strong significance.
This consistent growth stems from balanced expansion across all business divisions. The pharmaceutical division has strengthened market dominance through differentiated business models such as lyophilized injectable development, cutting-edge clinical protocols, and customized solution-based sales strategies. The wellness division also played a key role by successfully leading new product initiatives and expanding its portfolio.
In the veterinary medicine division, despite sluggish market conditions, Daehan New Pharm achieved approximately 10% year-on-year sales growth through customer-centered product development and on-site engagement, breaking the notion that the market has reached maturity and limited growth potential.
Within the human pharmaceutical portfolio, new products such as Newtor Tab.—a cardiovascular therapy—and New-DN Injection., an injectable used for post-skin graft wound care, have gained robust market traction. These new products now account for over 30% of total sales, further strengthening the company’s overall product portfolio.
Daehan New Pharm CEO Bae Gun-woo commented, “In our international operations, we are reinforcing partnerships with key markets such as Russia and China to achieve our global business objectives. We are also actively expanding into new markets including Mongolia and Australia, further building on the capabilities that earned us the ‘10 Million Dollar Export Tower’ award last year.”
He added, “Our sustained growth has been driven by differentiated solution development, creative sales strategies, and strong human capital. We are confident of reaching 110 billion KRW in annual sales and 12 billion KRW in operating profit in 2016. Looking ahead, we will continue this growth trajectory by strengthening R&D for improved pharmaceuticals, developing new growth engines in the bio and global sectors, and enhancing the core competencies of our key talent.” |


Home